Denali Suffers Another ALS Fail With Phase II/III Flop

By /

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and Amylyx have seen similarly disappointing results.

Scroll to Top